Article Figures & Data
Figures
- FIGURE 1.
Aromatase availability imaged by 11C-vorozole in women with breast cancer. (A) SUV map from patient with single lesion on mammography (arrow) before and after letrozole administration (blocking). Focal uptake is seen in tumor area at baseline, and decreased uptake is seen in tumor and heart. This pattern was observed in 6 of 10 patients. (B) SUV map from patient with single lesion on mammography (arrow), which did not show increased tracer uptake. This pattern was seen in 3 women. (C) CT (left) and PET overlaid on CT (right) from patient with stage IV metastatic cancer. Arrow indicates location of primary tumor on patient’s mammogram. (D) SUV maps of same patient. Node 1 arrow points to location and size identified on mammography. Multiple bone metastases and high-uptake area adjacent to primary tumor (node 2) can be seen with no apparent blocking.
- FIGURE 2.
11C-vorozole uptake in breast tissue contralateral to aromatase-overexpressing and non–aromatase-overexpressing tumors and breasts of healthy women. Bars depict mean and SEM for each group. One-way ANOVA demonstrated significant main effect of group (F2,14 = 5.94, P < 0.02). Fisher post hoc least significant difference test demonstrated highly significant difference (**P = 0.005) between healthy breasts (healthy, n = 5) and breasts contralateral to aromatase-overexpressing (positive, n = 7) lesion. Intermediate values, not significantly different from either group, were observed in breast tissue contralateral to aromatase-negative (negative, n = 3) lesions.
- FIGURE 3.
Mean tracer uptake in healthy breast and tumor over various intervals. Bars represent mean and SEM for 10 subjects (baseline scan). Emission acquisition began 40 min after tracer injection and continued for 50 min. SUV was averaged over entire acquisition (40–90 min) and several shorter intervals. There was no statistically significant difference (1-way ANOVA) among the various intervals.
- FIGURE 4.
Immunohistochemical staining for aromatase in biopsy material from breast cancer patients imaged with 11C-vorozole in vivo. (A and D) Patient with low-intensity labeling and low 11C-vorozole uptake. (B and E) Patient with moderately high staining intensity and moderately high 11C-vorozole uptake. (C and F) Patient with high staining intensity and high 11C-vorozole uptake. Top row is ×200; bottom row is ×400.
- FIGURE 5.
Quantitative immunohistochemical analysis of aromatase expression in patients with high and low vorozole uptake. (Left) Mean percentage of cells positively stained for aromatase among patients with high (above median, n = 5) and low (below median, n = 5) SUV. Difference was not statistically significant (P = 0.2). (Right) Mean staining intensity (density, 255 minus gray level) for aromatase among patients with high (above median, n = 5) and low (below median, n = 5) SUV. *P < 0.02, Student t test, 2-tailed.
Tables
Number Lesion SUVmean Lesion SUVmax % block mean SUVR mean 2 13.69 24.43 0 5.87 3 4.66 6.03 21.8 2.84 4 5.80 7.83 20.1 2.75 5 1.61 3.80 25.7 0.92 6 0.79 1.41 0 1.00 7 3.63 4.86 53.3 1.44 9 2.47 3.03 NA 1.91 10 1.78 4.40 3 1.01 11 3.20 4.09 56.3 1.80 12 2.61 3.98 18.9 1.73 %block = 100 − [(SUV after letrozole/SUV baseline) × 100]; NA = not available, no blocking study performed.
Supplemental Data
Files in this Data Supplement:
